Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
December 26, 2023
Assignee:
BIOSYNTIA APS
Inventors:
Hans Jasper Genee, Anne Pihl Bali, Nils Myling-Petersen
Abstract: The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.
Type:
Application
Filed:
July 12, 2018
Publication date:
June 22, 2023
Applicant:
BIOSYNTIA APS
Inventors:
Hans Jasper GENEE, Anne Pihl BALI, Nils MYLING-PETERSEN
Abstract: The invention relates to a genetically modified prokaryotic cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) and one or more transgenes or upregulated endogenous genes encoding iron-sulfur (Fe—S) cluster polypeptides or proteins that catalyze complex radical-mediated molecular rearrangements, electron transfer, radical or non-redox reactions, sulfur donation or perform regulatory functions. The prokaryotic cells are characterized by enhanced activity of these iron-sulfur (Fe—S) cluster polypeptides, enhancing their respective functional capacity, and facilitating enhanced yields of compounds in free and protein-bound forms, including heme, hemoproteins, tetrapyrroles, B vitamins, amino acids, ?-aminolevulinic acid, biofuels, isoprenoids, pyrroloquinoline quinone, ammonia, indigo, or their precursors, whose biosynthesis depends on their activity.
Type:
Application
Filed:
January 15, 2020
Publication date:
April 28, 2022
Applicant:
BIOSYNTIA APS
Inventors:
Hans Jasper GENEE, Carlos G. ACEVE-DO-ROCHA, Anne Pihl BALI, Lasse Holm LAURIDSEN, Luisa GRONENBERG, Nils MYLING-PETERSEN
Abstract: The present invention relates to a regulatable gene expression construct comprising a nucleic acid molecule comprising two or more regulation sequences encoding respective RNA molecules comprising a riboswitch responsive to an effector compound, said riboswitch being operably linked to a respective coding region which encodes a respective modulator compound for modulating the action of a respective growth regulator compound and each said riboswitch in each regulation sequence being selected be responsive to the same effector compound to trigger expression of its respective modulator compound. The invention also relates to a method of using the regulatable gene expression construct for selecting from a metagenomic library a primary modulator compound which effects a chemical transformation of a substrate into said effector compound or transports said effector compound into a micro-organism comprising the regulatable gene expression construct.
Abstract: The invention provides a genetically modified bacterium for production of thiamine; where the bacterium is characterized by a transgene encoding a thiamine monophosphate phosphatase (TMP phosphatase having EC 3.1.3.-) as well as transgenes encoding polypeptides that catalyze steps in the thiamine pathway. The genetically modified bacterium is characterized by enhanced synthesis and release of thiamine into the extracellular environment. The invention further provides a method for producing thiamine using the genetically modified bacterium of the invention; as well as the use of the genetically modified bacterium for extracellular thiamine production.
Type:
Application
Filed:
December 16, 2016
Publication date:
December 19, 2019
Applicant:
BIOSYNTIA APS
Inventors:
Luisa GRONENBERG, Bo SALOMONSEN, Matteo FERLA, Hans Jasper GENEE